ECSP109910A - Derivados de n-(arilamino) sulfonamidas que incluyen polimorfos como inhibidores de mek así como composiciones, métodos de uso y de preparación de los mismos - Google Patents

Derivados de n-(arilamino) sulfonamidas que incluyen polimorfos como inhibidores de mek así como composiciones, métodos de uso y de preparación de los mismos

Info

Publication number
ECSP109910A
ECSP109910A EC2010009910A ECSP109910A ECSP109910A EC SP109910 A ECSP109910 A EC SP109910A EC 2010009910 A EC2010009910 A EC 2010009910A EC SP109910 A ECSP109910 A EC SP109910A EC SP109910 A ECSP109910 A EC SP109910A
Authority
EC
Ecuador
Prior art keywords
compositions
methods
compounds
mek
arilamino
Prior art date
Application number
EC2010009910A
Other languages
English (en)
Inventor
Jean-Luc Girardet
Jean-Michel Vernier
Colin Edward Rowlings
Stuart Dimock
Barry Quart
Jeffrey N Miner
Original Assignee
Ardea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40304796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP109910(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/830,733 external-priority patent/US8101799B2/en
Application filed by Ardea Biosciences Inc filed Critical Ardea Biosciences Inc
Publication of ECSP109910A publication Critical patent/ECSP109910A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/28—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N41/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a sulfur atom bound to a hetero atom
    • A01N41/02—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a sulfur atom bound to a hetero atom containing a sulfur-to-oxygen double bond
    • A01N41/04—Sulfonic acids; Derivatives thereof
    • A01N41/06—Sulfonic acid amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)

Abstract

Esta invención se relaciona con compuestos N-(2-arilamino) aril sulfonamida que son inhibidores de MEK incluyendo formas polimórficas cristalinas que exhiben un perfil de difracción de rayos X en polvo específico y/o un perfil de calorimetría diferencial de barrido específico. Esta invención también se relaciona con composiciones farmacéuticas que comprenden los compuestos descritos y métodos de uso de los compuestos y composiciones descritos, incluyendo el uso en el tratamiento y/o prevención de cáncer, enfermedades hiperproliferativas y condiciones inflamatorias. La invención también se relaciona con métodos para obtener los compuestos y composiciones que se describen.
EC2010009910A 2007-07-30 2010-01-29 Derivados de n-(arilamino) sulfonamidas que incluyen polimorfos como inhibidores de mek así como composiciones, métodos de uso y de preparación de los mismos ECSP109910A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/830,733 US8101799B2 (en) 2005-07-21 2007-07-30 Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
US3446408P 2008-03-06 2008-03-06
US3446608P 2008-03-06 2008-03-06
US4488608P 2008-04-14 2008-04-14

Publications (1)

Publication Number Publication Date
ECSP109910A true ECSP109910A (es) 2010-04-30

Family

ID=40304796

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010009910A ECSP109910A (es) 2007-07-30 2010-01-29 Derivados de n-(arilamino) sulfonamidas que incluyen polimorfos como inhibidores de mek así como composiciones, métodos de uso y de preparación de los mismos

Country Status (23)

Country Link
EP (1) EP2184984A4 (es)
JP (3) JP2010535232A (es)
KR (3) KR20150091434A (es)
CN (2) CN101808516B (es)
AP (1) AP2817A (es)
AU (2) AU2008282338B2 (es)
BR (1) BRPI0815659A2 (es)
CA (1) CA2693390C (es)
CO (1) CO6470808A2 (es)
CR (1) CR11244A (es)
DO (1) DOP2010000045A (es)
EA (2) EA020624B1 (es)
EC (1) ECSP109910A (es)
HK (1) HK1147396A1 (es)
HN (1) HN2010000203A (es)
IL (1) IL203296A (es)
MA (1) MA31881B1 (es)
MX (1) MX2010001244A (es)
NZ (1) NZ582929A (es)
PH (1) PH12015501914A1 (es)
SV (1) SV2010003469A (es)
TN (1) TN2010000049A1 (es)
WO (1) WO2009018233A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
AU2009236325A1 (en) * 2008-04-14 2009-10-22 Ardea Biosciences, Inc. Compositions and methods for preparing and using same
TR201818979T4 (tr) * 2008-09-09 2019-01-21 Hoffmann La Roche Açil sülfonamidlerin polimorfları.
DK2331136T3 (en) 2008-09-26 2018-03-05 Oncomed Pharm Inc FRIZZLED BINDING AGENTS AND APPLICATIONS THEREOF
UY32486A (es) * 2009-03-11 2010-10-29 Ardea Biosciences Inc Tratamiento del cáncer de páncreas
MX2011009498A (es) * 2009-03-11 2011-10-14 Ardea Biosciences Inc Combinaciones farmaceuticas que comprenden rdea119/bay 869766 para el tratamiento de canceres especificos.
US9034861B2 (en) 2009-10-13 2015-05-19 Allomek Therapeutics Llc MEK inhibitors useful in the treatment of diseases
WO2011047788A1 (en) * 2009-10-21 2011-04-28 Bayer Schering Pharma Aktiengesellschaft Substituted benzosulphonamides
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
CN102020651B (zh) 2010-11-02 2012-07-18 北京赛林泰医药技术有限公司 6-芳基氨基吡啶酮甲酰胺mek抑制剂
CN102649773A (zh) * 2011-02-23 2012-08-29 苏州波锐生物医药科技有限公司 氨基芳香烃类化合物及其在制备抗恶性肿瘤药物中的用途
WO2012149493A2 (en) * 2011-04-28 2012-11-01 Sloan-Kettering Institute For Cancer Research Hsp90 combination therapy
EP2714652B8 (en) * 2011-05-27 2018-09-05 Ardea Biosciences, Inc. Chiral synthesis of n-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-6-methoxyphenyl}-1-[2,3-dihydroxy-propyl]cyclopropanesulfonamides
WO2013086260A2 (en) * 2011-12-09 2013-06-13 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of cancer
WO2013109142A1 (en) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Combined pdk and mapk/erk pathway inhibition in neoplasia
KR20150013332A (ko) * 2012-05-31 2015-02-04 바이엘 파마 악티엔게젤샤프트 간세포 암종(hcc) 환자 치료제의 효과적 반응을 결정하기 위한 바이오마커
CA2875986C (en) * 2012-06-04 2020-06-09 Pharmacyclics, Inc. Crystalline forms of a bruton's tyrosine kinase inhibitor
CA3079071C (en) * 2012-10-19 2022-06-07 Array Biopharma Inc. Preparation of crystallized benzimidazole derivative as mek inhibitor and formulation comprising same
WO2014071183A1 (en) 2012-11-02 2014-05-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor
CA2899353A1 (en) 2013-02-04 2014-08-07 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a wnt pathway inhibitor
EP2848246A1 (en) 2013-09-13 2015-03-18 Bayer Pharma Aktiengesellschaft Pharmaceutical compositions containing refametinib
US9629851B2 (en) 2013-09-20 2017-04-25 Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis ROCK in combination with MAPK pathway
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
WO2015156674A2 (en) 2014-04-10 2015-10-15 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
US11197896B2 (en) 2014-08-25 2021-12-14 Société des Produits Nestlé S.A. Egg protein formulations and methods of manufacture thereof
MD3265084T2 (ro) 2015-03-03 2024-05-31 Pharmacyclics Llc Formulări farmaceutice ale inhibitorului tirozin kinazei Bruton
MX2019015177A (es) * 2017-06-16 2020-02-07 Beta Pharma Inc Formulaciones farmaceuticas de n-(2-(2-(dimetilamino)etoxi)-4-meto xi-5((4-(1-metil-1h-indol-3-il)pirimidin-2-il)amino)fenil)acrilam ida y las sales de ellas.
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162117A (en) * 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
JP2575590B2 (ja) * 1992-07-31 1997-01-29 塩野義製薬株式会社 トリアゾリルチオメチルチオセファロスポリン塩酸塩およびその水和物結晶ならびにそれらの製法
PT810209E (pt) * 1992-08-25 2002-09-30 Searle & Co Hidroxietilamino-sulfonamidas de alfa- e beta-aminoacidos uteis como inibidores de protease retroviral
US7115632B1 (en) * 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
SK9822001A3 (en) * 1999-01-13 2002-08-06 Warner Lambert Co 1-heterocycle substituted diarylamines, pharmaceutical compositions based thereon and their use in therapy
GB0003224D0 (en) * 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
US7235567B2 (en) * 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
JP2005508322A (ja) * 2001-09-24 2005-03-31 ジェシー エル エス オウ 併用療法に用いられるスラミンの化学増感用量を決定するための方法及び成分
ZA200500418B (en) * 2002-07-17 2006-10-25 Titan Pharmaceuticals Inc Combination of chemotherapeutic drugs for increasing anitumor activity
AU2003253350B2 (en) * 2002-07-30 2008-06-26 Aeterna Zentaris Gmbh Use of alkyl phosphocholines in combination with antitumor medicaments
AU2006235487B2 (en) * 2005-04-12 2011-12-22 Elan Pharma International Limited Nanoparticulate quinazoline derivative formulations
KR20070122575A (ko) * 2005-04-22 2007-12-31 깃세이 야쿠힌 고교 가부시키가이샤 4'-｛2-[(1ｓ, 2ｒ)-2-히드록시-2-(4-히드록시페닐)-1-메틸에틸아미노]에톡시｝-3-이소프로필-3', 5'-디메틸비페닐-4-카르복실산 염산염의 결정 다형
DK1912636T3 (da) * 2005-07-21 2014-07-21 Ardea Biosciences Inc N-(arylamino)-sulfonamid-inhibitorer af mek
JP2007099763A (ja) * 2005-09-08 2007-04-19 Toyama Chem Co Ltd ピペラシリンナトリウム・１水和物の新規な結晶及びその製造方法
TW200800150A (en) * 2005-12-21 2008-01-01 Organon Nv Compounds with medicinal effects due to interaction with the glucocorticoid receptor

Also Published As

Publication number Publication date
KR20150091434A (ko) 2015-08-10
AU2008282338B2 (en) 2015-02-12
TN2010000049A1 (en) 2011-09-26
HK1147396A1 (en) 2011-08-12
EA032294B1 (ru) 2019-05-31
CN101808516B (zh) 2013-08-28
CA2693390C (en) 2017-01-17
KR20140098185A (ko) 2014-08-07
EA020624B1 (ru) 2014-12-30
SV2010003469A (es) 2010-04-30
EA201000268A1 (ru) 2010-08-30
HN2010000203A (es) 2012-11-19
CO6470808A2 (es) 2012-06-29
EP2184984A1 (en) 2010-05-19
IL203296A (en) 2017-06-29
AP2817A (en) 2013-12-31
DOP2010000045A (es) 2010-10-31
NZ582929A (en) 2012-03-30
EP2184984A4 (en) 2013-07-24
CA2693390A1 (en) 2009-02-05
MX2010001244A (es) 2010-08-31
CN103479604A (zh) 2014-01-01
PH12015501914A1 (en) 2017-07-31
JP6309880B2 (ja) 2018-04-11
CR11244A (es) 2010-05-20
AU2015200390B2 (en) 2017-02-23
CN103479604B (zh) 2016-08-10
CN101808516A (zh) 2010-08-18
MA31881B1 (fr) 2010-12-01
AU2008282338A1 (en) 2009-02-05
WO2009018233A1 (en) 2009-02-05
KR20100092424A (ko) 2010-08-20
JP2015078199A (ja) 2015-04-23
AP2010005134A0 (en) 2010-02-28
JP2017125021A (ja) 2017-07-20
EA201400552A1 (ru) 2014-09-30
BRPI0815659A2 (pt) 2014-09-30
JP2010535232A (ja) 2010-11-18

Similar Documents

Publication Publication Date Title
ECSP109910A (es) Derivados de n-(arilamino) sulfonamidas que incluyen polimorfos como inhibidores de mek así como composiciones, métodos de uso y de preparación de los mismos
DOP2016000271A (es) Compuestos de heteroarilo o arilo bicíclicos fusionados
UY37205A (es) Inhibidores de bromodominios
CR20110028A (es) Derivados de pirimidina como inhibidores de cinasa
CL2015002635A1 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
ECSP088749A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
CO6620050A2 (es) Derivados de aminopirimidina como moduladores de la lrrk2
UY31481A1 (es) Nuevos derivados de pirimidina, procesos de preparacion, composiciones farmacéuticas conteniéndolos y aplicaciones
ECSP077268A (es) Polimorfo ii de rapamicina y los usos de los mismos
UY33921A (es) Oxazinopteridinas y oxazinoptiridinonas n-sustituidas
CU20110235A7 (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
BR112012013431A2 (pt) composto, composição farmacêutica e seu uso
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
DOP2006000061A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
CO6531452A2 (es) Piperidinas sustituidas que aumentan la actividad de p53 y sus usos
UY31885A (es) Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
UY29420A1 (es) Derivados de 2-piridona,composiciones que los contienen, procesos de preparación y aplicación
UY35275A (es) Derivados de aminopirazina
CL2019001993A1 (es) Inhibidores selectivos de jak1.
UY37225A (es) Inhibidores del potenciador del homólogo zeste 2 campo de la invención
CO6321280A2 (es) Nueva clase espiro piperidinas para el tratamiento de enfermedades neurodegenerativas
CY1123880T1 (el) Καινοτομοι 5-ητ2 ανταγωνιστες
CR9257A (es) Polimorfo cci-779 y uso del mismo
ECSP18056196A (es) Derivados de indano
ECSP13012372A (es) Nuevos derivados 1,4-diazepanos, inhibidores de pde-5.